Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does CISPLATIN\PACLITAXEL Cause Second primary malignancy? 5 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with CISPLATIN\PACLITAXEL. This represents 26.3% of all adverse event reports for CISPLATIN\PACLITAXEL.

5
Reports of Second primary malignancy with CISPLATIN\PACLITAXEL
26.3%
of all CISPLATIN\PACLITAXEL reports
0
Deaths
0
Hospitalizations

How Dangerous Is Second primary malignancy From CISPLATIN\PACLITAXEL?

Of the 5 reports.

Is Second primary malignancy Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for CISPLATIN\PACLITAXEL. However, 5 reports have been filed with the FAERS database.

What Other Side Effects Does CISPLATIN\PACLITAXEL Cause?

Acute myeloid leukaemia (8) Lymphangioleiomyomatosis (8) Blast cells present (5) Haematocrit decreased (5) Haemoglobin decreased (5) Mean cell haemoglobin decreased (5) Mean cell volume abnormal (5) Neutrophil percentage decreased (5) Platelet count decreased (5) Red cell distribution width increased (5)

What Other Drugs Cause Second primary malignancy?

CYCLOPHOSPHAMIDE (1,247) DOXORUBICIN (1,151) VINCRISTINE (908) IMATINIB (763) PALBOCICLIB (658) RITUXIMAB (646) RUXOLITINIB (611) ETOPOSIDE (573) PREDNISONE (517) OCTREOTIDE (496)

Related Pages

CISPLATIN\PACLITAXEL Full Profile All Second primary malignancy Reports All Drugs Causing Second primary malignancy CISPLATIN\PACLITAXEL Demographics